Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

Status:
Completed

Trial end date:
2007-06-01

Target enrollment:

Participant gender:

To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes

Phase 2

Pfizer